Illumina, Inc. announced that it has appointed, Jacob Thaysen, as Chief Executive Officer with effect from September 25. Earlier, the Gene sequencing test maker had announced that it accepted the resignation of Francis deSouza as its CEO with effect from June 11. Thaysen, 48, currently serves as Senior Vice President of Agilent Technologies and President of its Life Sciences and Applied Markets Group.

Prior to Life Science and Applied Markets, he was President of Agilent's Diagnostics and Genomics Group from 2014 to 2018. Charles Dadswell, interim CEO of Illumina, will resume his position as Senior Vice President and General Counsel once Thaysen assumes his role. From October 2013 to November 2014 he served as Vice President and General Manager of Agilent?s Diagnostics and Genomics business.

Prior to that he served as Vice President and General Manager of Agilent?s Genomics Solutions unit from January 2013 to October 2013. Before joining Agilent, he served in various capacities at Dako A/S (?Dako?), a Danish diagnostics company, including as Corporate Vice President of R&D; Vice President, System Development, R&D; Vice President, Strategic Marketing; and Vice President, Global Sales Operations. Prior to Dako, Mr. Thaysen worked as a management consultant and Chief Technical Officer and founder of a high-tech start-up company.